Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.91 USD
+0.18 (3.70%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $4.90 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.91 USD
+0.18 (3.70%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $4.90 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
by Zacks Equity Research
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
by Zacks Equity Research
Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
by Zacks Equity Research
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
by Zacks Equity Research
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
by Zacks Equity Research
Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Vanda (VNDA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) concluded the recent trading session at $4.06, signifying a -1.46% move from its prior day's close.
Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
by Zacks Equity Research
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder
by Zacks Equity Research
Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
by Zacks Equity Research
AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
by Zacks Equity Research
Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.